Baxter International Inc. (BTL.F)
| Previous close | 32.46 |
| Open | 32.50 |
| Bid | 32.31 x 13000 |
| Ask | 32.62 x 12700 |
| Day's range | 32.25 - 32.50 |
| 52-week range | 29.45 - 44.20 |
| Volume | |
| Avg. volume | 35 |
| Market cap | 16.434B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.07 |
| Earnings date | 25 July 2024 - 29 July 2024 |
| Forward dividend & yield | 1.08 (3.32%) |
| Ex-dividend date | 31 May 2024 |
| 1y target est | 94.13 |
PR NewswireBAXTER ANNOUNCES MISSION AND LOGO FOR PROPOSED KIDNEY CARE COMPANY VANTIVE
Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.
ZacksBaxter's (BAX) Clinolipid Gets FDA's Expanded Indication
Baxter's (BAX) receipt of the latest expanded indication for Clinolipid is expected to meet the diverse nutritional needs of patients, ranging from preterm neonates to adults.
Business WireBaxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
DEERFIELD, Ill., May 13, 2024--Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates. Clinolipid is Baxter’s proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insuffici
